Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Clinical development of MVA-based therapeutic cancer vaccines.

Acres B, Bonnefoy JY.

Expert Rev Vaccines. 2008 Sep;7(7):889-93. doi: 10.1586/14760584.7.7.889. Review.

PMID:
18767940
2.

5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.

Amato RJ.

Expert Opin Biol Ther. 2010 Feb;10(2):281-7. doi: 10.1517/14712590903586213. Review.

PMID:
20088718
3.

The next generation of vaccines for the treatment of cancer.

Long L, Glover RT, Kaufman HL.

Curr Opin Mol Ther. 1999 Feb;1(1):57-63. Review. No abstract available.

PMID:
11249685
4.

[Cancer vaccines].

Kyte JA.

Tidsskr Nor Laegeforen. 2006 Nov 16;126(22):2969-73. Review. Norwegian.

5.

Recombinant viruses as a tool for therapeutic vaccination against human cancers.

Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P.

Immunol Lett. 2000 Sep 15;74(1):11-25. Review.

PMID:
10996623
6.

Tumor vaccine: current trends in antigen specific immunotherapy.

Baral R.

Indian J Exp Biol. 2005 May;43(5):389-406. Review.

PMID:
15900903
7.

Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.

Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.

Crit Rev Immunol. 2007;27(5):451-62. Review.

PMID:
18197807
8.

Poxviruses as vectors for cancer immunotherapy.

Kwak H, Hörig H, Kaufman HL.

Curr Opin Drug Discov Devel. 2003 Mar;6(2):161-8. Review.

PMID:
12669450
9.

Viral vectors for cancer immunotherapy.

Harrop R, Carroll MW.

Front Biosci. 2006 Jan 1;11:804-17. Review.

PMID:
16146772
10.

Clinical applications of recombinant virus-based cancer immunotherapy.

Adamina M, Daetwiler S, Rosenthal R, Zajac P.

Expert Opin Biol Ther. 2005 Sep;5(9):1211-24. Review.

PMID:
16120051
11.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
12.

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

Gómez CE, Nájera JL, Krupa M, Esteban M.

Curr Gene Ther. 2008 Apr;8(2):97-120. Review.

PMID:
18393831
13.

Immunotherapy against antigenic tumors: a game with a lot of players.

Pérez-Díez A, Marincola FM.

Cell Mol Life Sci. 2002 Feb;59(2):230-40. Review.

PMID:
11915941
14.

Carcinoembryonic antigen as a target for cancer vaccines.

Hodge JW.

Cancer Immunol Immunother. 1996 Nov;43(3):127-34. Review.

PMID:
9001565
15.

Therapeutic vaccines against melanoma and colorectal cancer.

Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P.

Vaccine. 2001 Mar 21;19(17-19):2571-5. Review.

PMID:
11257394
16.

5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.

Amato RJ.

Expert Opin Biol Ther. 2007 Sep;7(9):1463-9. Review.

PMID:
17727334
17.

Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer.

Nawrocki S, Wysocki PJ, Mackiewicz A.

Expert Opin Biol Ther. 2001 Mar;1(2):193-204. Review.

PMID:
11727529
18.

In situ cytokine gene transfection using vaccinia virus vectors.

Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ.

Semin Oncol. 1996 Feb;23(1):88-100. Review.

PMID:
8607035
19.

[Antitumor vaccines: conception, development and evaluation in humans].

Moingeon P.

Ann Pharm Fr. 2002 Jul;60(4):253-9. Review. French.

PMID:
12378152
20.

Cancer vaccine development: on the way to break immune tolerance to malignant cells.

Mocellin S, Rossi CR, Nitti D.

Exp Cell Res. 2004 Oct 1;299(2):267-78. Review.

PMID:
15350526

Supplemental Content

Support Center